LUND, Sweden--(BUSINESS WIRE)--Regulatory News: BioInvent International (STO:BINV) today announced that it has received another milestone payment from Bayer Pharma AG (Bayer) as the first patient was enrolled in a Phase I clinical trial of a second antibody identified from BioInvent’s n-CoDeR® library. The size of the milestone payment was not disclosed. This is the third milestone payment during the summer of 2014 received from international pharmaceutical companies, linked to success in the development of different antibodies from n-CoDeR®.
Help employers find you! Check out all the jobs and post your resume.
